@article{d216c51918c546b9b7f002ccc9cd6303,
title = "Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia",
abstract = "Hairy cell leukemia is an uncommon hematologic malignancy characterized by pancytopenia and marked susceptibility to infection. Tremendous progress in the management of patients with this disease has resulted in high response rates and improved survival, yet relapse and an appropriate approach to retreatment present continuing areas for research. The disease and its effective treatment are associated with immunosuppression. Because more patients are being treated with alternative programs, comparison of results will require general agreement on definitions of response, relapse, and methods of determining minimal residual disease. The development of internationally accepted, reproducible criteria is of paramount importance in evaluating and comparing clinical trials to provide optimal care. Despite the success achieved in managing these patients, continued participation in available clinical trials in the firstline and particularly in the relapse setting is highly recommended. The Hairy Cell Leukemia Foundation convened an international conference to provide common definitions and structure to guide current management. There is substantial opportunity for continued research in this disease. In addition to the importance of optimizing the prevention and management of the serious risk of infection, organized evaluations of minimal residual disease and treatment at relapse offer ample opportunities for clinical research. Finally, a scholarly evaluation of quality of life in the increasing number of survivors of this now manageable chronic illness merits further study. The development of consensus guidelines for this disease offers a framework for continued enhancement of the outcome for patients.",
author = "Grever, {Michael R.} and Omar Abdel-Wahab and Andritsos, {Leslie A.} and Versha Banerji and Jacqueline Barrientos and Blachly, {James S.} and Call, {Timothy G.} and Daniel Catovsky and Claire Dearden and Judit Demeter and Monica Else and Francesco Forconi and Alessandro Gozzetti and Ho, {Anthony D.} and Johnston, {James B.} and Jeffrey Jones and Gunnar Juliusson and Eric Kraut and Kreitman, {Robert J.} and Loree Larratt and Francesco Lauria and Gerard Lozanski and Emili Montserrat and Parikh, {Sameer A.} and Park, {Jae H.} and Aaron Polliack and Quest, {Graeme R.} and Rai, {Kanti R.} and Farhad Ravandi and Tadeusz Robak and Alan Saven and Seymour, {John F.} and Tamar Tadmor and Tallman, {Martin S.} and Constantine Tam and Enrico Tiacci and Xavier Troussard and Zent, {Clive S.} and Thorsten Zenz and Zinzani, {Pier Luigi} and Brunangelo Falini",
note = "Funding Information: Conflict-of-interest disclosure: L.A.A. received research support from Sanofi; V.B. consulted for Roche, Lundbeck, Gilead, and Janssen (all related to chronic lymphocytic leukemia); C.D. is on an advisory board/receives honoraria from Roche, Medimmune, Gilead, Janssen, and AbbVie; B.F. along with E.T. filed a patent on the discovery of BRAF mutation in hairy cell leukemia and received research funding from Roche; F.F. is on an advisory board for Infinity and has received honoraria from Gilead, AbbVie, and Janssen; M.R.G. serves on an advisory board regarding ibrutinib for Pharmacyclics and a data safety monitoring board for Acerta; A.D.H. serves on an advisory committee/board for Daimler and Benz Foundation and forGenzyme-Sanofi and Roche and has received research funding from Sanofi; J.J. has received research funding and drugs (ibrutinib) from Pharmacyclics for a hairy cell leukemia clinical trial; G.J. has advised Merck and EMD Serono regarding cladribine in multiple sclerosis; S.A.P. has received research funding from Pharmacyclics; F.R. has received research funding from MedImmune; J.F.S. has received honoraria and travel support from and participated in a speaker's bureau for Roche; C.T. has received honorarium and research funding from Janssen-Cilag and AbbVie; X.T. had research funding from Roche and received honoraria or served as advisor or consultant for Roche and Gilead; C.S.Z. had research funding from GlaxoSmithKline, Novartis, Genzyme, and Biothera; P.L.Z. has consulted for Bayer AG, Sandoz, and Morphosis; has participated in a speaker's bureau for Celgene, Pfizer, Takeda, Gilead, Janssen, and Teva; has received honoraria from Celgene, Roche, Teva, Gilead, Janssen, Takeda, and Pfizer; and has participated in advisory boards for Bayer AG, Celgene, Roche, Gilead, Janssen, Takeda, and TG Pharmaceuticals. The remaining authors declare no competing financial interests. Publisher Copyright: {\textcopyright} 2011 by The American Society of Hematology; all rights reserved.",
year = "2017",
month = feb,
day = "2",
doi = "10.1182/blood-2016-01-689422",
language = "English",
volume = "129",
pages = "553--560",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",
}